Novo Nordisk's pricing strategies in the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, that has accused the company of value gouging, pointing out the stark distinction involving U.S. costs and people in Europe and copyright.The manufacturer claims that suitable utilization of copyright, in addition to food plan and exercise,